Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
Daniel W. Sherbenou(University of Colorado Anschutz Medical Campus), Michael W. Deininger(Versiti Blood Center of Wisconsin), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Laura McGreevey(Novartis (Switzerland)), Brian Druker(Oregon Health & Science University), Patina M. Harrell(Naval Health Research Center), Richard D. Press(Oregon Health & Science University), Michael C. Heinrich(VA Portland Health Care System), Adil Humayun(Oregon Health & Science University), Matthew J. Wong, Rui Yang(Tianjin University of Science and Technology)
Cited by 77
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464